Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 6,022

Document Document Title
WO/2010/132982A1
It is reported herein that certain muscle diseases and conditions, including forms of muscular dystrophy, are characterized by impaired insulin-dependent signaling in the muscle tissue, in essence, a form of insulin resistance. The prese...  
WO/2010/127991A1
The present invention relates to a method for preparing fluoroalkanesulphinic acid esters. The invention specifically relates to the preparation of esters of trifluoromethanesulphinic acid, commonly referred to as "triflinic acid". The m...  
WO/2010/104177A1
A fluoroalkanesulfinic acid ammonium salt is obtained using an organic base when a bromofluoroalkyl carboxylate ester is sulfinated using a sulfinating agent. The fluoroalkanesulfinic acid ammonium salt is oxidized, thereby obtaining a f...  
WO/2010/104178A1
An ammonium hydroxyfluoroalkanesulfinate is obtained by using an organic base while sulfinating a bromofluoroalcohol with a sulfinating agent. An ammonium hydroxyfluoroalkanesulfonate is obtained by oxidizing said ammonium hydroxyfluoroa...  
WO/2010/100337A1
The present invention relates to novel prodrugs of metformin, their pharmaceutically acceptable salts, pharmaceutical compositions containing the prodrugs, and methods of using the prodrugs. In particular, the present invention relates t...  
WO/2010/096677A2
Compounds are provided that comprise dinitroso-derivatives of dihydrolipoic acid. Pharmaceutical compositions comprising the compounds and methods of using the compounds for treating various diseases and disorders, including angina, hype...  
WO/2010/050392A1
An aimed alkoxycarbonylfluoroalkanesulfonic acid salt is obtained by using a halofluoroalkanoic acid ester as a starting raw material, and by sulfinating the ester in the presence of an amine (step 1) and then oxidizing the resulting pro...  
WO/2010/037693A1
The invention relates to a method for purifying trifluoromethanesulfinic acid by azeotropic distillation using an aromatic solvent, to a method for producing purified trifluoromethanesulfinic acid, and to the use of the purified trifluor...  
WO/2010/013687A1
A perfluoroalkanesulfonyl halide is reacted with hydrazine to obtain a perfluoroalkanesulfinic acid hydrazine salt (RfSO2H·N2H4). The hydrazine salt obtained is reacted with a base such as an alkali metal hydroxide to obtain a perfluor...  
WO/2009/133052A1
The present invention relates to a compound of formula (I), including any stereochemically isomeric form thereof, wherein the substituents are as defined in the specification and the claims; a N-oxide thereof, a pharmaceutically acceptab...  
WO/2009/128907A1
Processes useful for making a pharmaceutically useful compound according to Formula (I), forms of such a compound, and intermediates useful in such processes are described.  
WO/2009/099902A1
Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described here...  
WO/2009/068533A1
The present invention relates to a method for preparing a highly pure trifluoromethanesulphinic acid. The method of the invention for preparing a highly pure trifluoromethanesulphinic acid, starting from an aqueous mixture comprising a t...  
WO/2009/068534A1
The present invention relates to a method for preparing a salt of trifluoromethanesulphinic acid termed "triflinic acid". More specifically, the invention relates to a method for preparing a highly pure triflinic acid salt. The method of...  
WO/2009/009041A2
The invention relates to compounds and methods for modulating one or more components of a kinase cascade.  
WO/2008/110698A2
The invention relates to a method for preparing polyfluorinated sulphanylamides of formula (I) and polyfluorinated sulphinamidines of formula (II), wherein R1-R4 are defined as in the claims, and for preparing the precursors of same.  
WO/2008/038640A1
Disclosed is a salt of trans-4-sulfinylamino-1-cyclohexanecarboxylic acid. Also disclosed is a method for producing a salt of trans-4-sulfinylamino-1-cyclohexanecarboxylic acid.  
WO/2008/009816A2
The invention relates to aromatic sulfinates and sulfonyl halides, and to the preparation thereof. The halides and the sulfinates are respectively of formulae Ar-Z- (CF2) n-CFRf-SO2Y (I) and [Ar-Z- (CF2) n-CFRf-SO2] m M wherein Z is a su...  
WO/2007/128893A1
The present invention concerns an improved method for preparing oxysulfide and fluorinated organic derivatives. The invention relates to the preparation of perfluoroalkanesulfinic and sulfonic acids, and preferentially trifluoromethanesu...  
WO/2007/107311A2
The invention relates to special sulphinic acid derivatives of formula (I), wherein M represents a hydrogen atom or an equivalent of a monovalent or polyvalent cation, R is derived from a peptide or represents a group according to one of...  
WO/2006/106800A1
Disclosed is a method for producing a compound (III), a salt thereof or a solvate of them by reacting a compound (I), a salt thereof or a solvate of them with a compound (II) in a toluene solvent in the presence of an additive such as wa...  
WO/2006/059252A2
Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease. Also described are methods, compounds, pharmaceutical compositions and kits for detecting, diagnosing, monitoring ...  
WO/2006/050471A2
Acyloxyalkyl carbamate prodrugs of 3-aminopropylsulfinic acid and analogs thereof, pharmaceutical compositions of 3-aminopropylsulfinic acid and analogs thereof, methods of making prodrugs of 3-aminopropylsulfinic acid and analogs thereo...  
WO/2006/030208A1
The present invention relates to enantiopure, non-proteinogenic &agr -amino acids, and methods for the synthesis thereof, that are useful as, or in the synthesis of, pharmaceutical, nutraceutical or agricultural products.  
WO/2005/067502A2
Compounds of the formula (I) which are modulators of chemokine receptor activity useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including al...  
WO/2005/063018A1
Present invention relates to a haloalkene compound of the formula (I)or its salt: wherein each of X1 and X2 is halogen; Y is alkyl, haloalkyl or phenyl; n is 0 to 5; L is -C(=B)Q, -C(=B)B’Q, -C(=B)N(D)Q, -N(D)Q, -N(D)C(=B)Q, -N(D)C(=B)...  
WO/2005/035591A1
Compositions are provided that include an electron donor and a sensitizing compound. More specifically, the electron donor is an arylsulfinate salt. Methods of polymerization are also provided that can be used to prepare polymeric materi...  
WO/2005/035590A1
Compositions are provided that that can be used as an initiator system for free radical polymerization reactions. More specifically, the initiator systems include an electron acceptor and an electron donor. The electron donors are arylsu...  
WO/2005/034885A1
Compositions are provided that include a photoinitiator system for free radical polymerization reactions. More specifically, the photoinitiator includes an arylsulfinate ion and a triarylsulfonium ion. Polymerization methods are also pro...  
WO/2004/072087A2
The invention relates to novel metal complexes for optical data carriers, whereby the latter is preferably a transparent substrate which is, optionally already covered with one or several reflective layers. A light-inscriptible informati...  
WO/2004/026814A2
The invention is a process for the preparation of compounds of the Formula (I): where R1, R2, R3, R4 and R5 are defined in the specification, which are intermediates useful for the preparation of tubulin inhibitors useful in the treatmen...  
WO/2004/024130A2
Treatment of central nervous system disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthal enamine and with (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthal enamine is disclose...  
WO/2004/018414A2
The present invention relates to compounds of formula I or a pharmaceutically acceptable salt thereof, wherein X=NH Y=CO, CS, -C(=N-CN) or X and Y together form an alkene, or C3-C5 cycloalkyl; R1 is -COOH; R2 is an electron withdrawing g...  
WO/2004/002950A1
A sulfenyl compound represented by the general formula R-S-X (1) (wherein R represents an organic group having at least one constituent element labeled with an isotope; and X represents a leaving group); a labeling reagent containing the...  
WO/2004/000856A1
The present invention relates to a medicament comprising, separately or together, (i) at least one reflux inhibitor; and (ii) at least one imidazopyridine. A further aspect of the invention relates to methods of treatment of gastro-esoph...  
WO/2004/000855A1
The present invention relates to a medicament comprising, separately or together, (i) at least one acid secretion inhibiting agent; and (ii) at least one reflux inhibitor. A further aspect of the invention relates to methods of treatment...  
WO/2003/106407A1
A process for the production of fluorine-containing fluorosulfonylalkyl vinyl ethers represented by the general formula: CF2=CFO(CF2CF(CF3)O)nCF2(CF2CF2)mCF2SO2F (wherein m is an integer of 0 to 5 and n is an integer of 0 to 10), charact...  
WO/2003/091204A1
The present invention relates to novel compounds of formula (I), or a salt, solvate, or physiologically functional derivative thereof, to a process for their manufacture, to pharmaceutical compositions containing them, and to their use i...  
WO/2003/091207A2
This invention provides a method of preparing amine stereoisomers, which comprises stereoselectively reducing a sulfinylimine that bears on the sulfmyl group a residue of an alcohol, thiol or amine, or reacting a sulfmylimine stereoisome...  
WO/2003/086282A2
The invention describes novel nitric oxide donors and novel compositions comprising at least one nitric oxide donor. The invention also provides novel compositions comprising at least one nitric oxide donor, and, optionally, at least one...  
WO/2003/076374A1
A process for producing a compound (I) which comprises the step of reacting a compound (II) with a base in an aprotic solvent as shown by the scheme: (II) (I) wherein R1 and R2 each independently represents lower alkyl.  
WO/2003/059873A1
This invention relates to novel compounds characterized by the general Formula (I) any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, or an N-oxide thereof, useful as potassium channe...  
WO2002039965B1
The invention relates to a reducing composition for the permanent deformation of the hair comprising an N-substituted formamidinesulphinic acid derivative as reducing agent and to a process for the permanent deformation of the hair emplo...  
WO/2003/050066A1
This invention is directed to functionalized higher diamondoids having at least one functional group. These derivatives have a higher diamondoid nucleus and up to six independently selected functional groups. The functionalized higher di...  
WO/2003/032908A2
The present invention relates to novel prodrugs of pharmaceutical compounds containing one or more N-H bonds. More specifically, the present embodiment of the invention relates to prodrugs wherein sulfur-containing promoieties are attach...  
WO/2003/011844A2
The invention concerns a composition for perfluoroalkylation of an electrophilic substrate. Said composition comprises for successive or simultaneous addition: a) at least one of the compounds of formula (I) Rf-Z(O)¿n?-Y, wherein: Z rep...  
WO/2003/004091A2
The present invention discloses novel sulfenate derivatives and their bioconjugates for phototherapy of tumors and other lesions. The sulfenates of the present invention are designed to absorb low-energy ultraviolet, visible, or near-inf...  
WO/2002/102250A1
A positron emission tomography (PET)-ready library of candidate pharmaceutical agents is provided which can be prepared by a multistep process wherein the final or penultimate step is a reaction using a PET-ready reagent or a plurality o...  
WO/2002/100823A1
Novel compounds of formula (I) wherein R¿1? represents hydrogen; R¿2? represents hydroxy, fluoro or an oxo group;R¿3? represents hydrogen; R¿4? represents hydrogen; and pharmaceutically acceptable salts, solvates and the stereoisomer...  
WO/2002/096516A1
A method is provided for the prevention or inhibition of cardiovascular disease comprising the admiministration of a cyclooxygenase-2 selective inhibitor with a dose of radiation.  

Matches 51 - 100 out of 6,022